Cytokinetics is a biopharmaceutical company focused on muscle biology and small-molecule therapies that modulate muscle function. Its pipeline targets cardiac and neuromuscular conditions, including hypertrophic cardiomyopathy and heart-failure related indications. The firm’s science centres on myosin and related contractile proteins rather than broad primary-care markets. Commercial scale remains limited while late-stage programmes advance.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 66.8 | — | -134.4 | — |
| Q3 2025 | 1.9 | — | -306.2 | — |
| Q4 2025 | 17.8 | — | -183 | — |
| Q1 2026 | 19.4 | — | -206 | — |
| Q2 2026 | 28.6 | -57.1% | -198.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Chord Energy Corporation (CHRD), Hut 8 Corp. (HUT), Bruker Corporation (BRKR), Protagonist Therapeutics, Inc. (PTGX), Lineage, Inc. (LINE), TG Therapeutics, Inc. (TGTX)